Skip to main content
Clinical Trials/CTRI/2021/11/038345
CTRI/2021/11/038345
Not Yet Recruiting
N/A

To evaluate the safety and efficacy of skin care regime with combination of Bristaa Intense Cream and Photostable Gold Sunscreen Gel in female subjects with melasma and dark spots. - N/AP

Sun Pharmaceutical Industries Limited0 sites0 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Sun Pharmaceutical Industries Limited
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1 Having Fitz Patrick Skin type III\-IV
  • 2 Having dark spots on face (with at least one dark spot ââ?°Â¥ 3\.5mm in diameter) or having visible melasma on face (with mMASI score between 1\-8\)
  • 3 Having dull skin (i.e., skin that lacks brightness \& has uneven skin tone based on visual assessment by experts)

Exclusion Criteria

  • 1Female who is pregnant or breastfeeding or has stopped breastfeeding in the past three months
  • 2Participating in another study liable to interfere with this study
  • 3Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area
  • 4Being insulin\-dependent diabetic or non insulin\-dependent diabetic with a recent therapy (less than 6 months)
  • 5Having progressive asthma
  • Being epileptic
  • Having non stabilized thyroid problems
  • Having cutaneous hypersensitivity
  • Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex
  • Following a chronic medicinal treatment comprising any of the following products: aspirin\-based products, anti\-inflammatories, anti\-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) for more than 1 year.

Outcomes

Primary Outcomes

Not specified

Similar Trials